Wenhuan Xiao1, Fei Ye1, Chunlai Liu2, Xiaowei Tang1, Jin Li1, Hui Dong1, Weiwei Sha1, Xiaobin Zhang3. 1. Department of Psychiatry, Affiliated WuTaiShan Hospital of Medical College of Yangzhou University, Yangzhou 225003, PR China. 2. Department of Psychiatry, Affiliated Kangren Hospital, Ili Kazak Autonomous Prefecture of Xinjiang 835000, PR China. 3. Department of Psychiatry, Affiliated WuTaiShan Hospital of Medical College of Yangzhou University, Yangzhou 225003, PR China. Electronic address: zhangxiaobim@163.com.
Abstract
OBJECTIVES: Evidence suggests that brain-derived neurotrophic factor (BDNF) and glial cell line -derived neurotrophic factor (GDNF) are important in the regulation of synaptic plasticity, which plays a key role in the cognitive processes in psychiatric disorders. Our work aimed at exploring the associations between serum BDNF and GDNF levels and cognitive functions in first-episode drug-naïve (FEDN) patients with schizophrenia. METHODS: The BDNF and GDNF levels of 58 FEDN patients and 55 age- and sex-matched healthy controls were measured and test subjects were examined using several neurocognitive tests including the verbal fluency test (VFT), the trail making test (TMT), the digit span test (DST), and the Stroop test. RESULTS: Patients performed significantly worse than controls in nearly all neurocognitive performances except the forward subscale part of the DST. BDNF levels were inversely correlated to TMT-part B scores and positively correlated to VFT-action in the FEDN group. GDNF levels showed a positive correlation with VFT-action scores and a negative correlation with TMT-part B scores of these patients. CONCLUSION: Current data suggests that cognitive dysfunction widely exists in the early stages of schizophrenia. BDNF and GDNF may be jointly contributed to the pathological mechanisms involved in cognitive impairment in FEDN patients with schizophrenia.
OBJECTIVES: Evidence suggests that brain-derived neurotrophic factor (BDNF) and glial cell line -derived neurotrophic factor (GDNF) are important in the regulation of synaptic plasticity, which plays a key role in the cognitive processes in psychiatric disorders. Our work aimed at exploring the associations between serum BDNF and GDNF levels and cognitive functions in first-episode drug-naïve (FEDN) patients with schizophrenia. METHODS: The BDNF and GDNF levels of 58 FEDN patients and 55 age- and sex-matched healthy controls were measured and test subjects were examined using several neurocognitive tests including the verbal fluency test (VFT), the trail making test (TMT), the digit span test (DST), and the Stroop test. RESULTS:Patients performed significantly worse than controls in nearly all neurocognitive performances except the forward subscale part of the DST. BDNF levels were inversely correlated to TMT-part B scores and positively correlated to VFT-action in the FEDN group. GDNF levels showed a positive correlation with VFT-action scores and a negative correlation with TMT-part B scores of these patients. CONCLUSION: Current data suggests that cognitive dysfunction widely exists in the early stages of schizophrenia. BDNF and GDNF may be jointly contributed to the pathological mechanisms involved in cognitive impairment in FEDN patients with schizophrenia.
Authors: Mei Hong Xiu; Zezhi Li; Da Chun Chen; Song Chen; Maile E Curbo; Hanjing Emily Wu; Yong Sheng Tong; Shu Ping Tan; Xiang Yang Zhang Journal: Schizophr Bull Date: 2020-12-01 Impact factor: 9.306
Authors: Lawrence H Yang; Bernalyn Ruiz; Amar D Mandavia; Margaux M Grivel; Liang Y Wong; Michael R Phillips; Matcheri S Keshavan; Huijun Li; Jeffrey A Lieberman; Ezra Susser; Larry J Seidman; William S Stone Journal: Schizophr Res Date: 2020-04-05 Impact factor: 4.939
Authors: Rodrigo R Nieto; Andrea Carrasco; Sebastian Corral; Rolando Castillo; Pablo A Gaspar; M Leonor Bustamante; Hernan Silva Journal: Front Psychiatry Date: 2021-06-16 Impact factor: 4.157